Genmab Announces AbbVie Receives Positive CHMP Opinion for
Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary efficacy and...
Source: globenewswire.com
Page 2 - Cell Surface News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Cell Surface. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Cell Surface Today - Breaking & Trending Today
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Jul 21, 2023--
Source: valdostadailytimes.com
Global Cell Surface Markers Analysis Report 2023: High Uptake in Drug Discovery Applications Widens Market Prospects
/PRNewswire/ -- The "Cell Surface Markers: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Cell Surface...
Source: prnewswire.com
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas
Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) foll...
Source: businessinsider.com
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in
COPENHAGEN, Denmark--(BUSINESS WIRE)--Epcoritamab featured in multiple data disclosures, including four oral presentationsResults presented from the phase 1b/2 EPCORE™ NHL-2 trial of epcoritamab combined with standard salvage therapy in patients with transplant eligible relapsed/refractory (R/R) diffuse large B-cell...
Source: pharmiweb.com